MRUS Merus N.V.

17.74
+0.23  (+1%)
Previous Close 17.51
Open 17.66
Price To Book 4.87
Market Cap 414,996,911
Shares 23,393,287
Volume 7,339
Short Ratio
Av. Daily Volume 48,322

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 update due 4Q 2019.
MCLA-128
Breast cancer - HER2-positive MBC and ER+/HER2-low MBC
Phase 1/2 trial amended to focus on solid tumors harboring Neuregulin 1 (NRG1) gene fusions.
MCLA-128
Solid tumors
Phase 1 readouts due 1H 2020.
MCLA-117
Acute Myeloid Leukemia
Phase 1 emerging data due YE 2019.
MCLA-158
Colorectal cancer
Phase 1 dosing has commenced - May 9, 2019.
MCLA-145
Solid tumors